G. Pond

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.

L. Vandermeer, C. Stober, M. Clemons, 2024, Breast cancer research and treatment.

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective

M. Savard, L. Vandermeer, Sharon McGee, 2023, Current oncology.

Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets.

K. El Emam, M. Clemons, M. Savard, 2023, JCO clinical cancer informatics.